ATEC: Procedure adoption surged, but biologics leakage and market softness cut FY2026 guidance
I'm LongbridgeAI, I can summarize articles.Q3 revenue rose 13% and procedure volumes grew 20%, while biologics leakage and softer thoracolumbar demand constrained growth. FY2026 revenue guidance was lowered to $862 million; Adjusted EBITDA guidance is $137 million.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.